Work

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide monotherapy (enza mono): EMBARK post hoc analysis

Year: 2025

Type: article

Source: European Urology Open Science

DOI: 10.1016/s2666-1683(25)01458-2

Authors: S.J. Freedland, U. De Giorgi, R.F. Tutrone, L.I. Karsh, M. Ramirez-Backhaus, E.M. Uchio, A.S. Rannikko, Y. Tang, R. Croitoru, M. Rosales, M. Kalac, F. Wang, N.D. Shore

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,800

OpenAlex ID: W4416188099

FWCI:

Cites:

Cited by:

Related to: 10